Elimination of hepatitis C in Australia by 2030: a decade and counting.
作者信息
Dore Gregory J
机构信息
Infectious diseases physician, St Vincent's Hospital, Sydney.
出版信息
Aust Prescr. 2021 Apr;44(2):36-37. doi: 10.18773/austprescr.2021.003. Epub 2021 Apr 1.
Abstract
摘要
相似文献
1
Elimination of hepatitis C in Australia by 2030: a decade and counting.到2030年在澳大利亚消除丙型肝炎：十年倒计时。
Aust Prescr. 2021 Apr;44(2):36-37. doi: 10.18773/austprescr.2021.003. Epub 2021 Apr 1.
2
Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.在澳大利亚新南威尔士州直接作用抗病毒治疗时代，丙型肝炎病毒相关肝病负担下降。
J Hepatol. 2019 Aug;71(2):281-288. doi: 10.1016/j.jhep.2019.04.014. Epub 2019 May 10.
3
Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C.直接作用抗病毒疗法可降低丙型肝炎肝硬化患者肝癌复发率。
Liver Int. 2017 Aug;37(8):1122-1127. doi: 10.1111/liv.13456. Epub 2017 May 25.
4
Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study.接受 DAA 治疗的晚期丙型肝炎患者新诊断的肝细胞癌：一项前瞻性人群研究。
J Hepatol. 2018 Aug;69(2):345-352. doi: 10.1016/j.jhep.2018.03.009. Epub 2018 Mar 16.
5
[Diagnosis and treatment strategies of hepatitis C-related hepatocellular carcinoma in the era of direct-acting antiviral drugs].[直接作用抗病毒药物时代丙型肝炎相关肝细胞癌的诊断与治疗策略]
Zhonghua Gan Zang Bing Za Zhi. 2020 Oct 20;28(10):827-830. doi: 10.3760/cma.j.cn501113-20200914-00516.
6
Hepatitis C virus relapse after successful treatment with direct-acting antivirals, followed by sarcomatous changes in hepatocellular carcinoma: a case report.直接作用抗病毒药物治疗后成功的丙型肝炎病毒复发，随后发生肝细胞癌肉瘤样改变：一例报告。
J Med Case Rep. 2020 May 27;14(1):62. doi: 10.1186/s13256-020-02392-y.
7
Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia.在澳大利亚，增强抗病毒治疗效果及提高治疗可及性，以预防丙型肝炎相关肝病负担和成本的不断上升。
J Gastroenterol Hepatol. 2014 Aug;29 Suppl 1:1-9. doi: 10.1111/jgh.12677.
8
[Hepatitis C-related hepatocellular carcinoma and the treatment with direct-acting antiviral agents].[丙型肝炎相关肝细胞癌与直接抗病毒药物治疗]
Zhonghua Gan Zang Bing Za Zhi. 2017 Dec 20;25(12):944-947. doi: 10.3760/cma.j.issn.1007-3418.2017.12.013.
9
Early development of de novo hepatocellular carcinoma after direct-acting agent therapy: Comparison with pegylated interferon-based therapy in chronic hepatitis C patients.直接作用抗病毒药物治疗后新发肝细胞癌的早期发生：与慢性丙型肝炎患者聚乙二醇干扰素治疗的比较
J Viral Hepat. 2018 Oct;25(10):1189-1196. doi: 10.1111/jvh.12918. Epub 2018 May 17.
10
Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.直接作用抗病毒治疗后慢性丙型肝炎患者的临床结局：一项前瞻性队列研究。
Lancet. 2019 Apr 6;393(10179):1453-1464. doi: 10.1016/S0140-6736(18)32111-1. Epub 2019 Feb 11.
引用本文的文献
1
Acceptability of automatic screening for viral hepatitis in an emergency department setting: patient and healthcare worker perspectives.急诊科环境下病毒性肝炎自动筛查的可接受性：患者和医护人员的观点。
Intern Med J. 2025 Sep;55(9):1491-1499. doi: 10.1111/imj.70157. Epub 2025 Jul 23.
2
From Education to Action-The Impact of Hepatitis C Micro-Elimination Education on Healthcare Provider Confidence and Linkage to Care: A Quasi-Experimental Study.从教育到行动——丙型肝炎微消除教育对医疗服务提供者信心及与护理联系的影响：一项准实验研究
Health Sci Rep. 2025 Jul 11;8(7):e71039. doi: 10.1002/hsr2.71039. eCollection 2025 Jul.
3
Liver disease trends in the Asia-Pacific region for the next 50 years.未来50年亚太地区的肝病趋势。
Clin Mol Hepatol. 2025 Jul;31(3):671-684. doi: 10.3350/cmh.2025.0043. Epub 2025 Mar 4.
4
Practical solutions to resolve social barriers to hepatitis C treatment initiation among people who inject drugs: a qualitative study.解决注射吸毒者中丙型肝炎治疗起始社会障碍的实用解决方案：一项定性研究
Harm Reduct J. 2024 Dec 20;21(1):221. doi: 10.1186/s12954-024-01136-1.
5
Elimination of HCV Infection: Recent Epidemiological Findings, Barriers, and Strategies for the Coming Years.消除 HCV 感染：近年流行病学发现、障碍及未来策略。
Viruses. 2024 Nov 19;16(11):1792. doi: 10.3390/v16111792.
6
HCV elimination: is the bulk of the iceberg being missed?丙型肝炎病毒消除：大部分冰山被遗漏了吗？
Gastroenterol Rep (Oxf). 2024 Oct 15;12:goae093. doi: 10.1093/gastro/goae093. eCollection 2024.
7
The Application of Australian Rights Protections to the Use of Hepatitis C Notification Data to Engage People 'Lost to Follow Up'.澳大利亚权利保护措施在利用丙型肝炎通报数据联系“失访”人群方面的应用
Public Health Ethics. 2024 May 17;17(1-2):40-52. doi: 10.1093/phe/phae006. eCollection 2024 Apr-Jul.
8
Global Elimination of HCV-Why Is Poland Still So Far from the Goal?全球消除 HCV——为什么波兰仍如此之远？
Viruses. 2023 Oct 9;15(10):2067. doi: 10.3390/v15102067.
9
Time-to-hepatitis C treatment initiation among people who inject drugs in Melbourne, Australia.澳大利亚墨尔本注射吸毒人群开始丙型肝炎治疗的时间。
Epidemiol Infect. 2023 May 9;151:e84. doi: 10.1017/S0950268823000675.
10
The 11th Canadian Symposium on Hepatitis C Virus: 'Getting back on track towards hepatitis C elimination'.第11届加拿大丙型肝炎病毒研讨会：“重回消除丙型肝炎的正轨”
Can Liver J. 2023 Feb 28;6(1):56-69. doi: 10.3138/canlivj-2022-0034. eCollection 2023 Feb.
本文引用的文献
1
High hepatitis C treatment uptake among people with recent drug dependence in New South Wales, Australia.澳大利亚新南威尔士州近期有药物依赖史人群中丙型肝炎的高治疗参与率。
J Hepatol. 2021 Feb;74(2):293-302. doi: 10.1016/j.jhep.2020.08.038. Epub 2020 Sep 12.
2
Hepatitis C elimination in Australia: progress and challenges.澳大利亚丙型肝炎消除工作：进展与挑战
Med J Aust. 2020 May;212(8):362-363. doi: 10.5694/mja2.50584. Epub 2020 Apr 19.
3
Global elimination of hepatitis C virus by 2030: why not?到2030年全球消除丙型肝炎病毒：为何不可以？
Nat Med. 2020 Feb;26(2):157-160. doi: 10.1038/s41591-019-0706-x.
4
Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.在澳大利亚新南威尔士州直接作用抗病毒治疗时代，丙型肝炎病毒相关肝病负担下降。
J Hepatol. 2019 Aug;71(2):281-288. doi: 10.1016/j.jhep.2019.04.014. Epub 2019 May 10.
5
Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia.澳大利亚注射吸毒人群中直接抗丙型肝炎病毒药物的快速使用与病毒血症流行率下降之间的关联。
J Hepatol. 2019 Jan;70(1):33-39. doi: 10.1016/j.jhep.2018.09.030. Epub 2018 Oct 25.
6
Uptake of direct-acting antiviral treatment for chronic hepatitis C in Australia.澳大利亚慢性丙型肝炎直接抗病毒治疗的接受情况。
J Viral Hepat. 2018 Jun;25(6):640-648. doi: 10.1111/jvh.12852. Epub 2018 Feb 19.
7
Hepatitis C virus therapeutic development: in pursuit of "perfectovir".丙型肝炎病毒治疗药物研发：追求“完美药物”
Clin Infect Dis. 2015 Jun 15;60(12):1829-36. doi: 10.1093/cid/civ197. Epub 2015 Mar 11.
Zotero 插件